Actylis and Novo Nordisk Pharmatech Announce a Strategic Partnership for the Distribution of Benzalkonium Chloride in Targeted European Countries.
Retrieved on:
Monday, March 25, 2024
Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland.
Key Points:
- Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland.
- By combining Novo Nordisk Pharmatech’s leading position as a manufacturer of the highest standards of pharmaceutical grade quaternary ammonium compounds (Quats), with Actylis’ expertise and infrastructure in critical raw material distribution, we aim to provide our customers with the best end-to-end service and quality.
- “We are thrilled to strengthen our collaboration with Actylis; this will extend our high standards to these fundamental European markets.
- We look forward to a successful partnership in the coming years,” says Samia Kappe, Chief Commercial Officer at Novo Nordisk Pharmatech A/S.